Nerviano Medical Sciences - Part of NMS Group’s Post

We are thrilled to announce that we’ll be speaking at the 15th Annual WADC 2024 in San Diego! ✨ 📅 Event Dates: 4 – 7 November 2024 📍 Location: San Diego, CA Join us as we explore new partnership opportunities and share insights on the future of our industry. We look forward to seeing you there! Link: https://lnkd.in/dk8GkWrh #WADC2024 #Partnerships #SanDiego #FutureOpportunities #Networking

𝗡𝗲𝗿𝘃𝗶𝗮𝗻𝗼 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝗮𝘁 𝗕𝗜𝗢-𝗘𝘂𝗿𝗼𝗽𝗲 𝟮𝟬𝟮𝟰 Nerviano Medical Sciences announces the participation in BIO-Europe 2024, <<https://lnkd.in/dnuNZ2D>> Europe's premier life sciences partnering event. - In-Person Event: November 4–6, 2024, Stockholm, Sweden  - Digital Partnering: November 12–13, 2024 We look forward to meeting you at the event and discussing potential collaborations. #BioEurope #NMS #lifesciences #NMSgroup #Biotech #Pharma

𝗡𝗲𝗿𝘃𝗶𝗮𝗻𝗼 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝗮𝗻𝗻𝗼𝘂𝗻𝗰𝗲𝘀 𝗽𝘂𝗯𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝘁𝗵𝗲 𝗽𝗮𝗽𝗲𝗿 "𝗣𝗿𝗲𝘀𝗲𝗻𝘁 𝗦𝗰𝗲𝗻𝗮𝗿𝗶𝗼 𝗮𝗻𝗱 𝗙𝘂𝘁𝘂𝗿𝗲 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲 𝗼𝗳 𝗣𝗮𝘆𝗹𝗼𝗮𝗱𝘀 𝗳𝗼𝗿 𝗔𝗗𝗖𝘀: 𝗙𝗼𝗰𝘂𝘀 𝗼𝗻 𝗗𝗡𝗔-𝗜𝗻𝘁𝗲𝗿𝗮𝗰𝘁𝗶𝗻𝗴 𝗔𝗴𝗲𝗻𝘁𝘀" We are pleased to announce the publication of our review article "𝗣𝗿𝗲𝘀𝗲𝗻𝘁 𝗦𝗰𝗲𝗻𝗮𝗿𝗶𝗼 𝗮𝗻𝗱 𝗙𝘂𝘁𝘂𝗿𝗲 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲 𝗼𝗳 𝗣𝗮𝘆𝗹𝗼𝗮𝗱𝘀 𝗳𝗼𝗿 𝗔𝗗𝗖𝘀: 𝗙𝗼𝗰𝘂𝘀 𝗼𝗻 𝗗𝗡𝗔-𝗜𝗻𝘁𝗲𝗿𝗮𝗰𝘁𝗶𝗻𝗴 𝗔𝗴𝗲𝗻𝘁𝘀s" in Pharmaceuticals, as part of the Special Issue "Evaluation of the Antitumor Mechanism of Armed Antibodies: 2nd Edition". This paper explores the latest advances in the use of DNA-interacting agents as payloads for antibody-drug conjugates (ADCs). It offers valuable insights into how these agents can be optimized for the development of more effective and safer therapeutic options for patients. Read the full article here: <<https://lnkd.in/dGzDrHKi>>. #ADCs #CancerResearch #Pharmaceuticals #OncologyInnovation #MDPIOpenAccess

𝗟𝗶𝘀𝗮 𝗠𝗮𝗵𝗻𝗸𝗲, 𝗠𝗗, 𝗣𝗵𝗗, 𝗽𝗮𝗻𝗲𝗹𝗶𝘀𝘁 𝗮𝘁 𝗔𝘅𝗶𝗼𝗺 𝗖𝗿𝗼𝘀𝘀𝗿𝗼𝗮𝗱𝘀 𝗦𝘂𝗺𝗺𝗶𝘁 We are proud to announce that Lisa Mahnke, MD, PhD, President, Board Member, Chief Executive & Medical Officer, will be a panelist at the Clinical Trial Design session during the Axiom Crossroads Summit <<https://lnkd.in/dt3a8dEK>>. The event takes place on October 10 at the MassBio Hub in Cambridge, MA. The summit brings together leading experts from academia, biopharma, and the investment community to explore innovative strategies for overcoming the challenges of R&D and clinical trials, with a focus on oncology and rare diseases. To participate in this impactful discussion, a donation to the Axiom REACH Foundation <<https://lnkd.in/gGknG8zH>> is encouraged. The Foundation is committed to reducing public health disparities by supporting underserved patients, families, and communities facing life-altering diagnoses. #Axion_Cross_Roads_Summit #clinical_trials #AXIONTHINKTANK #Axiom_REACH_Foundation #NMS

𝐋𝐢𝐬𝐚 𝐌𝐚𝐡𝐧𝐤𝐞, 𝐌𝐃, 𝐏𝐡𝐃, 𝐆𝐮𝐞𝐬𝐭 𝐒𝐩𝐞𝐚𝐤𝐞𝐫 𝐚𝐭 𝐭𝐡𝐞 8𝐭𝐡 𝐀𝐧𝐧𝐮𝐚𝐥 𝐃𝐃𝐑 𝐈𝐧𝐡𝐢𝐛𝐢𝐭𝐨𝐫𝐬 𝐒𝐮𝐦𝐦𝐢𝐭 We are proud to announce that Lisa Mahnke, MD, PhD, President, Board Member, Chief Executive & Medical Officer, was invited as a Guest Speaker at the 8th Annual DDR Inhibitors Summit <<https://lnkd.in/eUUeThyU>>. The summit, taking place in Boston January 28-30, is the community hotspot for biopharma drug developers and researchers to collaborate on advancing DDR therapeutics. 100+ experts from discovery, preclinical, translational, regulatory, and clinical roles will unite to harness the potential of DDR inhibitors for cancer treatment and enhance patient outcomes. Full event guide link <<https://lnkd.in/dhmwxtfK>> #DDR_inhibitors #NMS #PARP

𝐍𝐌𝐒-𝐔𝐏𝐎 𝐩𝐚𝐩𝐞𝐫 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐨𝐧 𝐭𝐡𝐞 𝐜𝐨𝐯𝐞𝐫 𝐨𝐟 𝐂𝐡𝐞𝐦𝐢𝐬𝐭𝐫𝐲 𝐀 𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐉𝐨𝐮𝐫𝐧𝐚𝐥 𝐓𝐮𝐫𝐧𝐢𝐧𝐠 𝐭𝐡𝐞 𝐈𝐦𝐩𝐨𝐬𝐬𝐢𝐛𝐥𝐞 𝐢𝐧𝐭𝐨 𝐑𝐞𝐚𝐥𝐢𝐭𝐲:  A chemical astronaut harnesses blue light irradiation to activate Passerini products containing a Hantzsch ester, derived from what are considered “impossible aldehydes.” Be sure to check out the stunning artwork created by Francesca Brunelli, one of the authors of our latest paper in collaboration with Prof. Professor Gian Cesare Tron (Università del Piemonte Orientale, UPO). The paper, published in the prestigious journal Chemistry - A European Journal, was also selected for the journal’s cover (https://lnkd.in/dqQA4ynj )!

𝐍𝐞𝐫𝐯𝐢𝐚𝐧𝐨 𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐒𝐜𝐢𝐞𝐧𝐜𝐞𝐬 𝐒𝐫𝐥 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐬 𝐁𝐑𝐀𝐅𝐓𝐎𝐕𝐈® 𝐑𝐨𝐲𝐚𝐥𝐭𝐲 𝐀𝐠𝐫𝐞𝐞𝐦𝐞𝐧𝐭 𝐰𝐢𝐭𝐡 𝐁𝐥𝐮𝐞 𝐎𝐰𝐥 𝐂𝐚𝐩𝐢𝐭𝐚𝐥, 𝐩𝐨𝐭𝐞𝐧𝐭𝐢𝐚𝐥𝐥𝐲 𝐞𝐱𝐜𝐞𝐞𝐝𝐢𝐧𝐠 $80 𝐌𝐢𝐥𝐥𝐢𝐨𝐧 - NMS to receive in excess of $50 Million in upfront cash and milestone payments; total returns capped at a multiple of investment - Financing proceeds will be used to advance NMS’ current pipeline and ADC platform NERVIANO, Italy and BOSTON, Mass., September 5 2024 - Nerviano Medical Sciences S.r.l. (NMS), a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS S.r.l, focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, today announced an agreement with funds managed by Blue Owl Capital (“Blue Owl”). This investment will enable NMS to monetize $80 million or more in potential future BRAFTOVI®  royalties, with Blue Owl providing in excess of $50 million in upfront cash and contingent proceeds. Under the terms of the agreement, NMS retains all subsequent royalties tied to BRAFTOVI® 's global net sales once a specific multiple of Blue Owl’s investment has been met, which in NMS’s estimation are anticipated to exceed $30 million. “This non-dilutive capital infusion allows us to strengthen our balance sheet to focus on our strategic priorities, after an important exercise to further prioritize and reinforce efforts on our core clinical programs.” said Hugues Dolgos, Pharm.D., Chief Executive Officer, NMS. “Main part of the proceeds will be used to advance and expand our pipeline and accelerate the development of our ADC platform. We are delighted to see that our confidence in the commercial opportunity of BRAFTOVI®  is aligned with that of Blue Owl through this transaction.”     “We are delighted to enter into this royalty monetization transaction with NMS, whose foundational IP contributed to the development and commercialization of Pfizer’s BRAFTOVI® .” said Sandip Agarwala, Managing Director at Blue Owl. “Our structurally flexible approach to investing in the life sciences allowed us to design a mutually rewarding transaction, and we are excited for the company to reinvest these proceeds into high potential R&D programs.” 𝐓𝐫𝐚𝐧𝐬𝐚𝐜𝐭𝐢𝐨𝐧 𝐓𝐞𝐫𝐦𝐬 Upon closing the BRAFTOVI® royalty agreement, NMS will receive in excess of $50 million in upfront cash and contingent payments based on a U.S. Food and Drug Administration approval milestone. The transaction allows NMS to maintain royalties in excess of a multiple of Blue Owl’s purchase price, with NMS projecting these earnings to surpass $30 million. Read More: https://lnkd.in/dTdmFd3u